SFSusan Fotheringham

Susan Fotheringham

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Susan Fotheringham has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Defining Challenge Conditions for Nipah Virus in the Syrian Golden Hamster Model: Effects of Dose, Exposure Route and Viral Strain

    by Emma Kennedy, Stephen Findlay-Wilson, Francisco J. Salguero, Ines Ruedas-Torres, Susan Fotheringham, Linda Easterbrook, Victoria A. Graham, Sarah Kempster, Neil Almond, Stuart D. Dowall

    Nipah virus (NiV) is a highly pathogenic zoonotic virus for which no licensed vaccines or therapeutics are currently available, necessitating well-characterised animal models to support countermeasure development. This study aimed to establish an appropriate challenge dose in the Syrian golden hamster model at the UK Health Security Agency (UKHSA), incorporating both intraperitoneal (i.p.) and intranasal (i.n.) routes of infection and two clinically relevant strains, NiV-Malaysia (NiV-M) and NiV-Bangladesh (NiV-B). Due to a different challenge doses and susceptibilities of hamsters to NiV being reported in the literature, there is a prerequisite to define the model parameters upon establishment in a new facility. Dose-ranging studies were performed across multiple independent experiments assessing survival, clinical progression and histopathological outcomes. Challenge via the i.p. route produced consistent and severe disease using an infectious dose of 103 TCID50 for both strains. In contrast, animals were more susceptible to infection via i.n. challenge with a dose of 10 TCID50 resulting in uniform lethality. For both challenge routes, respiratory and neurological disease manifestations were observed. These distinct disease phenotypes were supported by histopathological findings and viral RNA distribution in affected organs. Differences between strains were evident, with NiV-B showing a tendency towards a broader pulmonary pathology at lower doses after i.n. challenge. Collectively, these findings demonstrate that challenge dose, route of exposure, and viral strain influence disease outcomes in the hamster model.

  • Open Access

    Susceptibility and transmission of mpox virus infection in brown rats (Rattus norvegicus)

    by Lucy Crossley, Stephen Findlay-Wilson, Linda Easterbrook, Emma Kennedy, Francisco J. Salguero, Kim Mackay, Victoria Graham, Susan Fotheringham, Stuart Dowall

    A corrigendum of this article has been published full details can be found at https://doi.org/10.1099/jgv.0.002162 . Mpox (formerly known as monkeypox) virus (MPXV) is the zoonotic pathogen of mpox disease in humans. Its increasing emergence outside of its endemic area has heightened the importance of investigating the virus’ prevalence and maintenance in sylvatic reservoirs. The common brown rat (Rattus norvegicus) can inhabit almost anywhere in the UK, posing a threat to zoonotic transmission to humans. Two independent studies were carried out; the first investigated the susceptibility of brown rats to MPXV infection with a clade IIb mpox strain via two challenge routes: intranasal and intradermal. The second study considered the transmission of MPXV between challenged and naïve brown rats. All animals were asymptomatic to mpox disease, although enzyme-linked immunosorbent assay (ELISA) confirmed subclinical infection in challenge groups. In the susceptibility study, reverse transcription PCR (RT-PCR) detected mpox DNA in the lung tissue and throat swabs within the intranasally inoculated group, in addition to viable virus observed from the intranasal throat swabs. In contrast, no virus was detected in either tissues or swabs in the intradermally inoculated group or control group. RT-PCR results from the transmission study detected mpox DNA in tissues and throat swabs taken from challenged animals. Viable virus was observed from tissues and swabs of intranasally challenged animals with infectious titres of ~102–104 TCID50 per millilitre. ELISA assays in the transmission study showed replicable results compared to the first susceptibility study in directly challenged animals alongside evidence of seroconversion in co-housed naïve animals. In conclusion, brown rats are susceptible to MPXV infection, as they have been demonstrated to maintain viable virus in the absence of clinical signs. Viral transmission of MPXV from infected rats to naïve rats was not observed by RT-PCR, although naïve rats did show antibody responses when exposed to infected rats indicating exposure to virus.


  • Open Access

    Comparison of Chikungunya Virus-Induced Disease Progression and Pathogenesis in Type-I Interferon Receptor-Deficient Mice (A129) and Two Wild-Type (129Sv/Ev and C57BL/6) Mouse Strains

    by Victoria A. Graham, Linda Easterbrook, Emma Rayner, Stephen Findlay-Wilson, Lucy Flett, Emma Kennedy, Susan Fotheringham, Sarah Kempster, Neil Almond, Stuart Dowall

    Chikungunya virus (CHIKV) is a mosquito-borne alphavirus causing a debilitating febrile illness with rheumatic disease symptoms of arthralgia and arthritis. Since its spread outside of Africa in 2005, it continues to cause outbreaks and disseminates into new territories. Intervention strategies are urgently required, including vaccination and antiviral approaches. To test efficacy, the use of small animal models is required. Two mouse strains, A129, with a deficiency in their type-I interferon (IFN) receptor, and C57BL/6 are widely used. A direct comparison of these strains alongside the wild-type parental strain of the A129 mice, 129Sv/Ev, was undertaken to assess clinical disease progression, viral loads in key tissues, histological changes and levels of sera biomarkers. Our results confirm the severe disease course in A129 mice which was not observed in the parental 129Sv/Ev strain. Of the two wild-type strains, viral loads were higher in 129Sv/Ev mice compared to C57BL/6 counterparts. Our results have established these models and parameters for the future testing of vaccines and antiviral approaches.


  • Open Access

    Pathogenesis of Rift Valley Fever Virus in a BALB/c Mouse Model Is Affected by Virus Culture Conditions and Sex of the Animals

    by Victoria A. Graham, Linda Easterbrook, Emma Kennedy, Emma Rayner, Stephen Findlay-Wilson, Lucy Flett, Emma Louise Wise, Samantha Treagus, Susan Fotheringham, Sarah Kempster, et al.

    Rift Valley fever virus (RVFV) is a mosquito-borne zoonotic pathogen causing disease in livestock and humans. Whilst initially restricted to the African continent, recent spread to the Arabian Peninsula has highlighted the likelihood of entry into new regions. Due to the absence of a regulatory-approved human vaccine, work is ongoing to develop and assess countermeasures. As such, small animal models play a pivotal role in providing information on disease pathogenesis and elucidating which intervention strategies confer protection. To develop and establish the BALB/c mouse model, we challenged mice with RVFV grown from two separate cell lines: one derived from mosquitoes (C6/36) and the other mammalian derived (Vero E6). Following infection, we assessed the clinical course of disease progression at days 1 and 3 post-challenge and evaluated viral tropism and immune analytes. The results demonstrated that RVFV infection was affected by the cell line used to propagate the challenge virus, with those grown in insect cells resulting in a more rapid disease progression. The lowest dose that caused uniform severe disease remained the same across both virus preparations. In addition, to demonstrate reproducibility, the lowest dose was used for a subsequent infection study using male and female animals. The results further demonstrated that male mice succumbed to infection more rapidly than their female counterparts. Our results establish an RVFV mouse model and key parameters that affect the course of disease progression in BALB/c mice.


  • Open Access

    Establishment of a Nipah Virus Disease Model in Hamsters, including a Comparison of Intranasal and Intraperitoneal Routes of Challenge

    by Stephen Findlay-Wilson, Lucy Flett, Francisco J. Salguero, Ines Ruedas-Torres, Susan Fotheringham, Linda Easterbrook, Victoria Graham, Stuart Dowall

    Nipah virus (NiV) is an emerging pathogen that can cause severe respiratory illness and encephalitis in humans. The main reservoir is fruit bats, distributed across a large geographical area that includes Australia, Southeast Asia, and Africa. Incursion into humans is widely reported through exposure of infected pigs, ingestion of contaminated food, or through contact with an infected person. With no approved treatments or vaccines, NiV poses a threat to human public health and has epidemic potential. To aid with the assessment of emerging interventions being developed, an expansion of preclinical testing capability is required. Given variations in the model parameters observed in different sites during establishment, optimisation of challenge routes and doses is required. Upon evaluating the hamster model, an intranasal route of challenge was compared with intraperitoneal delivery, demonstrating a more rapid dissemination to wider tissues in the latter. A dose effect was observed between those causing respiratory illness and those resulting in neurological disease. The data demonstrate the successful establishment of the hamster model of NiV disease for subsequent use in the evaluation of vaccines and antivirals.


  • Open Access

    SARS-CoV-2 Disease Severity in the Golden Syrian Hamster Model of Infection Is Related to the Volume of Intranasal Inoculum

    by Alastair Handley, Kathryn A. Ryan, Elizabeth R. Davies, Kevin R. Bewley, Oliver T. Carnell, Amy Challis, Naomi S. Coombes, Susan A. Fotheringham, Karen E. Gooch, Michael Charlton, et al.

    The golden Syrian hamster (Mesocricetus auratus) is now commonly used in preclinical research for the study of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the assessment of vaccines, drugs and therapeutics. Here, we show that hamsters inoculated via the intranasal route with the same infectious virus dose of prototypical SARS-CoV-2 administered in a different volume present with different clinical signs, weight loss and viral shedding, with a reduced volume resulting in reduced severity of disease similar to that obtained by a 500-fold reduction in the challenge dose. The tissue burden of the virus and the severity of pulmonary pathology were also significantly affected by different challenge inoculum volumes. These findings suggest that a direct comparison between the severity of SARS-CoV-2 variants or studies assessing the efficacy of treatments determined by hamster studies cannot be made unless both the challenge dose and inoculation volume are matched when using the intranasal route. Additionally, analysis of sub-genomic and total genomic RNA PCR data demonstrated no link between sub-genomic and live viral titres and that sub-genomic analyses do not provide any information beyond that provided by more sensitive total genomic PCR.


  • Open Access

    SARS-CoV-2 Disease Severity in the Golden Syrian Hamster Model of Infection is Related to the Volume of Intranasal Inoculum.

    by Alastair Handley, Kathryn A. Ryan, Elizabeth R. Davies, Kevin R. Bewley, Oliver T. Carnell, Amy Challis, Naomi S. Coombes, Susan A. Fotheringham, Karen E. Gooch, Michael Charlton, et al.

    The Golden Syrian hamster (Mesocricetus auratus) is now commonly used in preclinical research for the study of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the assessment of vaccines, drugs and therapeutics. Here we show that hamsters inoculated via the intranasal route with the same infectious virus dose of prototypical SARS-CoV-2 administered in a different volume present with different clinical signs, weight loss and viral shedding, with a reduced volume resulting in reduced severity of disease similar to that obtained by a 500-fold reduction in challenge dose. The tissue burden of virus and the severity of pulmonary pathology were also significantly affected by different challenge inoculum volumes. These findings suggest that direct comparison between the severity of SARS-CoV-2 variants or studies assessing the efficacy of treatments determined by hamster studies cannot be made unless both the challenge dose and inoculation volume are matched when using the intranasal route. Additionally, analysis of sub-genomic and total genomic RNA PCR data demonstrated no link between sub-genomic and live viral titres and that sub-genomic analyses do not provide any information beyond that provided by more sensitive total genomic PCR.